Sector News

Deshpande leaves Achillion, leaving CEO chair free for Truitt

May 2, 2018
Life sciences

Achillion has promoted Joseph Truitt to replace outgoing CEO Milind Deshpande, Ph.D. The change puts the person who has overseen Achillion’s business development and commercial strategy for almost a decade in charge of the biotech as it nears midphase complement factor D data.

Truitt joined Achillion in 2009 after previously working at Viropharma and a Johnson & Johnson unit. Back then, Achillion was an infectious disease player looking to carve out a piece of the hepatitis C market. Gilead put pay to that plan, prompting Deshpande to reposition Achillion as a specialist in complement biology.

That repositioning means the company Truitt is inheriting is significantly different than the one he joined. The big clinical milestones ahead of Achillion 2.0 relate to rare diseases, specifically the renal condition C3 glomerulopathy (C3G) and paroxysmal nocturnal hemoglobinuria (PNH). Achillion expects to have interim phase 2 data in C3G in the third quarter, with an update on a PNH to follow shortly after.

Achillion has set Truitt’s base salary at $560,000, 37% more than his base salary as EVP and COO but less than his predecessor pulled in. Truitt also stands to receive a bonus of up to 55% of his base salary if he hits certain goals. Last year, Truitt received 75% of his maximum possible bonus as reward for his role in Achillion’s business development and the offering of stock held by Johnson & Johnson.

The biotech signaled its intent to hand Truitt more responsibility in February when it gave him the role of president, which was previously held by Deshpande. That move came months after the board signed off on a $26,000 pay bump for Truitt and added EVP to his existing title of COO.

By Nick Paul Taylor

Source: Fierce Biotech

Related News

February 21, 2021

Sanofi invests in health tech firm Novadiscovery, boosting trial simulation platform and COVID-19 work

Life sciences

Novadiscovery uses its so-called JINKO platform that runs disease models on virtual patients to support decision-making and de-risk clinical development.

February 21, 2021

Gilead lets local HIV community groups take the lead with $3M grant

Life sciences

The pharma is pledging $3.2 million over two years to the Human Rights Campaign, the largest lesbian, gay, bisexual, transgender and queer (LGBTQ+) civil rights organization in the U.S.

February 21, 2021

Biotech company funds research project on diversity

Life sciences

In collaboration with Genmab, a new anthropological postdoc project at the Department of Anthropology will now explore and help develop the company’s efforts to ensure a diverse and inclusive workplace.

Send this to a friend